Table 1.
Pharmacological properties of biphasic and monophasic IJPs in the LES from wild-type CD1 mice
|
LES clasp |
LES sling |
|||||||||
|---|---|---|---|---|---|---|---|---|---|---|
| RMP (mV) | IJP AMPL (mV) | IJP Duratn (ms) | lsIJP APL (mV) | lsIJP Duratn (ms) | RMP (mV) | IJP AMPL (ms) | IJP Duratn (mV) | |||
| Atropine | Control n=5 | −43.2±3.3 | 24.6±1.6 | 711±69 | 6.3±1.4 | 11 914±1825 | n=4 | −43.1±1.8 | 12.5±1.1 | 1033±91 |
| 3 μM | −42.3±3.5 | 29.4±1.5 | 720±49 | 9.5±1.8 | 14 485±2097 | −42.5±1.7 | 17.5±1.8 | 191±108 | ||
| Change | 0.9±0.4 | 4.7±1.1* | 9.6±42.8 | 3.2±0.6* | 2570±286* | 0.5±1.2 | 5.0±1.2* | 58±73 | ||
| Atropine+apamin | Control n=5 | −41.8±2.4 | 29.4±2.1 | 749±42 | 9.1±1.9 | 14 639±1977 | n=6 | −39.4±2.1 | 19.5±2.6 | 989±96 |
| 300 nM | −35.3±2.7 | 17.9±1.6 | 1087±110 | 7.6±1.6 | 12 197±1645 | −32.1±3.1 | 14.9±1.4 | 996±49 | ||
| Change | 6.5±1.2* | 11.5±1.5* | 339±80* | 1.5±1.3 | 2442±1698 | 7.3±1.8* | 4.6±1.6* | 7±76 | ||
| Atropine+apamin+L-NAME | Control n=5 | −37.8±1.6 | 19.9±2.5 | 1085±76 | 8.3±1.4 | 13 347±2683 | n=3 | −39.6±3.8 | 19.5±3.5 | 1049±92 |
| 200 μM | −33.3±1.0 | 8.1±1.5 | 469±36 | 0.3±0.2 | N/M | −34.5±2.9 | 2.5±1.5 | N/M | ||
| Change | 4.5±1.9 | 11.8±1.3* | 616±70* | 8.0±1.2* | N/M | 5.1±1.8 | 17.0±3.3* | N/M | ||
| Atropine+apamin+NFA | Control n=6 | −38.5±1.8 | 19.7±1.7 | 996±109 | 8.4±1.4 | 14 641±1633 | n=2 | −37.1 −40.8 |
16.6 22.9 |
1043 1385 |
| 200 μM | −48.9±3.5 | 6.2±1.0 | 1161±207 | 2.3±0.4 | N/M | −61.6 −47.1 |
2.8 1.4 |
N/M N/M |
||
| Change | 10.1±2.5* | 13.5±2.2* | 166±191* | 6.0±1.1 | N/M | 24.5 6.3 |
13.8 21.5 |
N/M N/M |
||
Abbreviations: AMPL, amplitude; Duratn, half-amplitude duration; IJP, monophasic IJP or initial phase of biphasic IJP; LES, lower oesophageal sphincter; L-NAME, N-nitro-L-arginine methyl ester; LSIJP, long-lasting slow IJP; N/M, not measured or not measurable; RMP, resting membrane potential.
*P<0.05.